ライフサイエンスコーパス: traveler

1 relatively rare cause of malaria in returned travelers.

2 focus posttravel evaluation of ill returned travelers.

3 tract hundreds of thousands of international travelers.

4 ffer consistent pretravel preventive care to travelers.

5 -identified pretravel data for international travelers.

6 ics that collect data from ill international travelers.

7 o cause life-threatening illness in returned travelers.

8 amplification (LAMP) kit in febrile returned travelers.

9 C metro area to include leisure and business travelers.

10 for advice before travel or by ill returned travelers.

11 effectively boosted immunity in JE-MB-primed travelers.

12 n imported into many nonendemic countries by travelers.

13 f the overall population of US international travelers.

14 P. malariae diagnosis and clinical course in travelers.

15 rditis in regions where it is endemic and in travelers.

16 mptoms associated with NoV diarrhea in these travelers.

17 asmodium falciparum infections in short-term travelers.

18 eeded for prevention of malaria in long-term travelers.

19 of semen testing for Zika virus from 2 male travelers.

20 ave a higher risk of malaria than short-term travelers.

21 el surveillance data for 17,353 ill returned travelers.

22 children in developing countries and at-risk travelers.

23 ery of preventive travel-related care to VFR travelers.

24 influence disease risk in this population of travelers.

25 recent (1996-2003) evidence, addressing VFR travelers.

26 needed to properly address the needs of VFR travelers.

27 ted States; approximately 60% are among U.S. travelers.

28 logy and magnitude from those of traditional travelers.

29 disorders, shift workers, and transmeridian travelers.

30 n imported into many nonendemic countries by travelers.

31 a remains a common problem for international travelers.

32 ay not be representative of all ill returned travelers.

33 ber of cases distributed across the globe by travelers.

34 nd are mostly due to infections in returning travelers.

35 ing identifiable cause of fever in returning travelers.

36 Three travelers (0.5%) acquired carbapenemase-producing Entero

37 rabies immunoglobulin (HRIG) to only 7 of 50 travelers (14%) who sought care abroad and for whom HRIG

38 Only 58 travelers (5%) had received typhoid vaccine.

39 elers [65%]) or at nonacademic centers (1777 travelers [51%]).

40 Among 824 participating travelers, 574 provided fecal samples before and after t

41 refusal was most frequent in the South (1432 travelers [63%]) and in nonacademic centers (1178 travel

42 vaccinated were evaluated in the South (2262 travelers [65%]) or at nonacademic centers (1777 travele

43 lers [63%]) and in nonacademic centers (1178 travelers [66%]).

44 Twenty-four travelers (8%) required medical attention because of ill

45 Among international travelers, a single person was more often infected with

46 sible differential diagnoses of ill returned travelers according to destination and reason for travel

47 t travelers save money for longer trips when travelers adhere to malaria recommendations and prophyla

48 associated costs and benefits resulting from traveler adherence to malaria chemoprophylaxis were calc

49 Structured questionnaire completed by traveler and provider during pretravel consultation.

50 We measured pitting in 83 French travelers and 42 Malian children treated for malaria wit

51 s account for a high volume of international travelers and are at markedly increased risk of travel-r

52 t other key enteric pathogens can be used by travelers and clinicians in pre- and posttravel consulta

53 is a global health problem and of concern to travelers and deploying military personnel with developm

54 , so that they can protect the health of the travelers and family members and close friends who will

55 can assist clinicians to advise prospective travelers and guide pretravel preparation, including iti

56 osinophilia is a common finding in returning travelers and immigrants from parasite-endemic areas.

57 articularly useful in military personnel and travelers and in the control of outbreaks.

58 l studies of this emergent viral pathogen in travelers and other at-risk populations.

59 ellents are important prophylactic tools for travelers and populations living in endemic areas of mal

60 lity of Toscana virus infection in returning travelers and provides information on how to obtain test

61 d lead to therapeutic options for both space travelers and terrestrial patients.

62 Escherichia coli (ETEC) is a common cause of travelers' and postweaning diarrhea in humans and swine,

63 Bone loss is a critical concern for space travelers, and a dietary countermeasure would be of grea

64 ay not be representative of all ill returned travelers, and denominator data are unavailable.

65 one metabolism remain key concerns for space travelers, and ground-based models of space flight have

66 ance System: 123 (66.5%) occurred among U.S. travelers, and of these, 114 (92.7%) were attributed to

67 revent cryptosporidiosis, particularly among travelers, animal handlers, child caregivers, and swimme

68 Travelers are at risk of acquiring MRE in these regions,

69 la Paratyphi A is an emerging infection, and travelers are increasingly at risk.

70 Travelers are more likely to be sociodemographically adv

71 cannot estimate disease risk because healthy travelers are not included in the denominator.

72 Travelers are sentinels for global Zika virus circulatio

73 Clinicians encountering ill travelers arriving from countries with widespread Ebola

74 y currently drive clinical evaluation of ill travelers arriving from Sierra Leone, Liberia, and Guine

75 e associations were observed among nonimmune travelers as well as immigrants from endemic areas.

76 From February 2012 to April 2013, travelers attending 6 international vaccination centers

77 consultations saved healthcare payers a per-traveler average of $14 (9-day trip) to $372 (30-day tri

78 Twenty-one percent (90/430) of the travelers became colonized by ESBL-PE and none by CPE.

79 proven P. malariae monoinfections in Israeli travelers between January 2008 and January 2017 were ret

80 iated with malaria prevention provided to US travelers bound for West Africa.

81 Vivax malaria causes significant illness in travelers, but current first-line chemoprophylaxis agent

82 been described in hyperparasitemic nonimmune travelers, but it is unknown if African children are equ

83 Vivax malaria causes significant illness in travelers, but relapses of vivax malaria are not prevent

84 Three months after return, 4.7% of the travelers carried MRE.

85 ance of NoV infection in three international traveler cohorts with diarrhea acquired in three develop

86 For travelers, consultations resulted in a range of net cost

87 ndent risk factors, with up to 80% of TD+AB+ travelers contracting ESBL-PE.

88 er skin infections and nasal colonization in travelers contribute to the global spread of such strain

89 se in MMR vaccination of eligible U.S. adult travelers could reduce the likelihood of importation and

90 Long-term travelers, defined here as those traveling for periods o

91 agent, was demonstrated in the treatment of travelers diarrhea in Mexico.

92 Geographic region, occurrence of travelers' diarrhea (TD), age, and use of antimicrobial

93 imin provided 72% and 77% protection against travelers' diarrhea and antibiotic-treated travelers' di

94 appears promising as a chemoprophylaxis for travelers' diarrhea and as a treatment of portal systemi

95 Rifaximin is effective for the treatment of travelers' diarrhea and can be considered as the treatme

96 uals susceptible to Escherichia coli-induced travelers' diarrhea and in tear fluid derived from viral

97 NoVs were identified in 10.2% of cases of travelers' diarrhea and, overall, was the second most co

98 ed in the United States for the treatment of travelers' diarrhea caused by noninvasive diarrheagenic

99 Travelers' diarrhea causes substantial morbidity and pos

100 Travelers' diarrhea developed in 14.74% of participants

101 Large field studies of travelers' diarrhea for multiple destinations are limite

102 Rifaximin safely prevented travelers' diarrhea in Mexico, where most cases are caus

103 NoVs are important pathogens of travelers' diarrhea in multiple regions of the world.

104 tile diarrhea in the developing world and of travelers' diarrhea in visitors to these areas from indu

105 Recommended treatment for travelers' diarrhea includes the combination of an antib

106 When invasive travelers' diarrhea pathogens are suspected, an alternat

107 Rifaximin prevents travelers' diarrhea with minimal changes in fecal flora,

108 i (ETEC) is a leading cause of childhood and travelers' diarrhea, for which an effective vaccine is n

109 is responsible for causing severe infant and travelers' diarrhea, gastroenteritis and hemolytic uremi

110 t travelers' diarrhea and antibiotic-treated travelers' diarrhea, respectively (P < 0.001 for both),

111 In the groups that did not report travelers' diarrhea, rifaximin significantly reduced the

112 onducted for the treatment and prevention of travelers' diarrhea, the treatment of portal systemic en

113 received an antibiotic for self-treatment of travelers' diarrhea.

114 as the treatment of choice for uncomplicated travelers' diarrhea.

115 cognized as an important cause of infant and travelers' diarrhoea, exhibits an aggregative, stacked-b

116 nations and itineraries of Global TravEpiNet travelers differed from those of the overall population

117 ns and epidemiology of Zika virus disease in travelers exposed in the Americas.

118 ns and epidemiology of Zika virus disease in travelers exposed in the Americas.

119 f the least invasive methods to assess urban traveler exposure.

120 Through 2 international traveler-focused surveillance networks (GeoSentinel and

121 ed patients represent an increasing group of travelers, for business, tourism, and visiting friends a

122 Travelers from all regions except Southeast Asia present

123 Febrile travelers from countries with unique endemic pathogens p

124 among travelers from every region, although travelers from every region except sub-Saharan Africa an

125 ent causes of systemic febrile illness among travelers from every region, although travelers from eve

126 For travelers from nonendemic countries, Vero cell-derived v

127 the recognition of Ebola virus disease among travelers from West Africa, cases of Middle East respira

128 veillance of human movement patterns and key traveler groups, it is hoped that interventions can be i

129 Long-term travelers have a higher risk of malaria than short-term

130 e of NoVs as a cause of diarrhea acquired by travelers in developing countries is not well known.

131 athogen that causes diarrhea in children and travelers in developing countries.

132 High-risk illnesses in VFR travelers include childhood vaccine-preventable illnesse

133 d measles should target all vaccine-eligible travelers, including catch-up vaccination of susceptible

134 adverse outcomes of Zika virus disease among travelers infected in the Americas and show a need for g

135 adverse outcomes of Zika virus disease among travelers infected in the Americas and show a need for g

136 on affected millions of people, and infected travelers introduced CHIKV to new regions.

137 Prevention of malaria in long-term travelers is a complex issue and requires expert advice

138 ing of morbidity profiles among ill returned travelers is based on limited data from the 1980s.

139 Whether the effects are similar in air travelers is unknown.

140 avel health consultations help international travelers manage travel-related illness risks through ed

141 sure to ultraviolet B light, including space travelers, may not receive enough vitamin D.

142 To navigate efficiently, a traveler must establish a heading using a frame of refer

143 tions for prevention of malaria in long-term travelers must be individualized.

144 ond most common diagnosis among nonimmigrant travelers (n = 95 [12.3%]).

145 In travelers, O-iRBCs peaked at 107.7% initial parasitemia.

146 tious HIV-1 in semen becomes an adventitious traveler on the pathway leading to normal human reproduc

147 the profiles of the photographers to derive travelers' origins.

148 to be men (73% vs. 54% of low-infection risk travelers, P=0.018) or born outside the United Stated or

149 and pretravel healthcare of US international travelers, particularly those at higher risk of travel-a

150 Travelers planning to attend mass events will encounter

151 Among travelers presenting to GeoSentinel sites, systemic febr

152 ions can be implemented to protect and treat travelers, prevent onward transmission in low transmissi

153 In travelers primed with JE-MB, vaccination response rates

154 monly prescribed antimalarial drug, and most travelers received an antibiotic for self-treatment of t

155 Nonvaccination due to traveler refusal was most frequent in the South (1432 tr

156 e, 1689 (48%) were not vaccinated because of traveler refusal, 966 (28%) because of provider decision

157 series of JE-VC has been recommended to all travelers regardless of previous vaccination history.

158 Fifty-nine percent of travelers reported >/=1 medical condition.

159 Only 40.5% of all ill travelers reported pretravel medical visits.

160 Ninety-six percent of travelers reported that they did not seek specific pretr

161 Prevention of malaria in travelers requires detailed knowledge of malaria epidemi

162 ase, preventing illness in U.S. resident VFR travelers requires focused efforts to remove barriers to

163 ness occurred in only 26, 9, and 7 returning travelers, respectively.

164 es outside of ZIKV-endemic areas as infected travelers return to their home countries.

165 Ten Belgian travelers returned from Mali with a Schistosoma haematob

166 ctious to humans by describing the case of a traveler returning from the Central African Republic inf

167 Carriage lasted longer in travelers returning from Asia and in travelers with a hi

168 Knowledge of illness in travelers returning from Brazil can assist clinicians to

169 only a few cases have been reported in U.S. travelers returning from Europe, most cases are likely u

170 ost travel-associated infections occurred in travelers returning from Latin America and the Caribbean

171 1 October 2009-30 November 2009, 37 Israeli travelers returning from Nepal were diagnosed with S. Pa

172 . Paratyphi A infection was noted in Israeli travelers returning from Nepal.

173 rickettsiosis, occurring in as many as 5% of travelers returning from rural subequatorial Africa.

174 quency of occurrence of each diagnosis among travelers returning from six developing regions of the w

175 Among travelers returning from sub-Saharan Africa, rickettsial

176 ca and compare it to parasites isolated from travelers returning from these regions of Africa, as wel

177 ause of illness in West Africa and among the travelers returning from this region with an acute febri

178 Clinicians evaluating travelers returning ill from Malaysia with myalgia, with

179 cs that compute probabilities reminiscent of traveler's and divergent ratios.

180 ater, food and environmental samples as well traveler's baggage is a great challenge of the time for

181 encoding OPG (TNFRSF11B) are associated with traveler's diarrhea (TD) among North American travelers

182 Traveler's diarrhea (TD) is the most common infectious i

183 herichia coli (ETEC) is the leading cause of traveler's diarrhea and children's diarrhea worldwide.

184 n emerging diarrheal pathogen, implicated in traveler's diarrhea and endemic diarrhea in developing a

185 herichia coli (ETEC) is a prevalent cause of traveler's diarrhea and infant mortality in third-world

186 Prevention of traveler's diarrhea by dietary avoidance measures is oft

187 Acquiring traveler's diarrhea causes 12% to 46% of travelers to ch

188 is the standard treatment in self-therapy of traveler's diarrhea except when patients are in South or

189 Improved hygiene has reduced the risk of traveler's diarrhea from 20% or more (for a 2-week stay)

190 ugh improved hygiene has reduced the risk of traveler's diarrhea in many destinations, the risk remai

191 scherichia coli (ETEC) is a leading cause of traveler's diarrhea worldwide.

192 man diseases, including cholera, diphtheria, traveler's diarrhea, and whooping cough.

193 acterial enterotoxins, including cholera and traveler's diarrhea, remain a major global health proble

194 that is used in Europe as a preventative of traveler's diarrhea.

195 terial cause of diarrheal disease, including traveler's diarrhea.

196 ostridium difficile-associated diarrhea, and traveler's diarrhea.

197 olated from the stools of Danish adults with traveler's diarrhea.

198 with community-acquired gastroenteritis and traveler's diarrhea.

199 012-April 2014 was performed for articles on traveler's diarrhea.

200 occur in 3% to 17% of patients who have had traveler's diarrhea.

201 hat the cooperative behavior observed in the Traveler's Dilemma can be explained in an evolutionary f

202 an quantitatively reproduce data that from a Traveler's Dilemma experiment.

203 der behavior in one such social dilemma, the Traveler's Dilemma, that has received considerable atten

204 ired settings, as well as from patients with traveler's or persistent diarrhea.

205 perspectives: the healthcare payer's and the traveler's.

206 y for short- and longer-term trips, and that travelers save money for longer trips when travelers adh

207 Returning travelers seeking medical care have a diagnosis of gastr

208 sles immunity status of departing U.S. adult travelers seeking pretravel consultation and to assess r

209 Malaria remains a common diagnosis among travelers seen at GeoSentinel sites.

210 ed in sequential blood samples from returned travelers sent for pathogen testing to a specialist para

211 seling for those visiting high-risk regions, travelers should be advised against taking antibiotics f

212 Geographic variation in the risk of SSTIs in travelers supports a globally heterogeneous distribution

213 In returning travelers, the clinical assessment can provide substanti

214 In vaccine-naive travelers, the vaccination response rate for test strain

215 Unlike other travelers, they also face risks because of close contact

216 ective live vaccine (17D) is widely used for travelers to and residents of areas in which yellow feve

217 Travelers to Brazil will encounter locally endemic infec

218 imarily identified infectious diseases among travelers to Brazil.

219 ing traveler's diarrhea causes 12% to 46% of travelers to change their travel plans.

220 h generally SOTR were able to travel safely, travelers to destinations at high-risk for infection had

221 mmunodeficiency virus-infected patients, and travelers to developing regions of the world.

222 ia in pregnant women who are residents of or travelers to epidemic or endemic regions is needed to av

223 he geographic region, with 17 of 100 (17.0%) travelers to Guatemala, 23 of 194 (11.9%) travelers to I

224 ng hemodialysis patients), or HIV infection; travelers to HBV-endemic regions; and adults seeking pro

225 se of illness; illness was more likely among travelers to high-infection risk (18%) than low-risk (6%

226 accine that can rapidly protect short-notice travelers to high-risk areas and help control explosive

227 Travelers to India who had EAEC-associated diarrhea show

228 %) travelers to Guatemala, 23 of 194 (11.9%) travelers to India, and 3 of 79 (3.8%) travelers to Mexi

229 Approximately 40% of US travelers to less developed countries experience diarrhe

230 rhea is the most common illness that affects travelers to low-income regions of the world.

231 UNSPs from travelers to Mexico (33/37 [89.2%]) clustered with those

232 NoV infection is a frequent occurrence among travelers to Mexico and Guatemala who experience episode

233 1.9%) travelers to India, and 3 of 79 (3.8%) travelers to Mexico testing positive for NoVs from 2002

234 raveler's diarrhea (TD) among North American travelers to Mexico.

235 "-like outbreak was identified among Israeli travelers to Nepal.

236 of concern due to the potential for infected travelers to spread the virus to countries where vectors

237 evaluated N. meningitidis carriage among US travelers to the 2001 Hajj.

238 Approximately 8 percent of travelers to the developing world require medical care d

239 undifferentiated febrile illness (UFI) among travelers to the developing world, and these pathogens a

240 rhea in children of developing countries and travelers to these countries, is to protect against heat

241 ions at higher risk for infectious diseases; travelers to these destinations were more likely to be m

242 n or expatriates of developing countries and travelers to these regions where follow-up studies have

243 ea in infants in developing countries and in travelers to those regions.

244 The exact source of infection among travelers to Tioman Island remains unclear but needs to

245 Malaria commonly infects residents of and travelers to tropical regions.

246 MRE acquisition is very frequent among travelers to tropical regions.

247 Providers must counsel travelers to yellow fever (YF)-endemic areas, although r

248 We analyzed hematologic parameters in 123 travelers treated with AS for severe malaria.

249 Long-term travelers underuse personal protective measures and adhe

250 s where the disease burden is low (so-called travelers vaccines), they have demonstrated a lower prot

251 More than 300 million travelers visit regions with poor hygiene annually.

252 avel destination and reason for travel, with travelers visiting friends and relatives in their countr

253 the overall pooled relative risk for VTE in travelers was 2.0 (95% CI, 1.5 to 2.7).

254 xcluded, the pooled relative risk for VTE in travelers was 2.8 (CI, 2.2 to 3.7), without significant

255 The presence of PVL in S. aureus in travelers was associated with complicated disease, reduc

256 a and in the predominant genogroup infecting travelers was demonstrated, dependent upon the specific

257 on specific diagnosis among 770 nonimmigrant travelers was malaria (n = 310 [40.3%]), with Plasmodium

258 Compared with matched control patients, travelers were 74% more likely to be transplanted (aHR [

259 The pathogens identified most commonly in travelers were Campylobacter (42%), nontyphoidal Salmone

260 One hundred twenty travelers were divided into 4 groups: Volunteers with no

261 Inactivated vaccines given to European travelers were found to elicit protective levels of neut

262 40 810 adult travelers were included; providers considered 6612 (16%)

263 ndiarrheagenic E. coli isolates from healthy travelers were used as controls.

264 r's assessment, but fewer than half of these travelers were vaccinated.

265 The majority of Global TravEpiNet travelers were visiting low- or lower-middle-income coun

266 Seventy-five percent of travelers were visiting malaria-endemic countries, and 3

267 stance to common antimicrobials in returning travelers, where severe disease requires empirical treat

268 We report a traveler who acquired a Salmonella enterica subspecies e

269 and pretravel healthcare of US international travelers who are at increased risk of travel-associated

270 Chemoprophylaxis should be restricted to travelers who are at risk of severe complications of dia

271 ation is highly recommended for all overseas travelers who are without documented proof of adequate i

272 We describe 1586 ill returned travelers who had visited Brazil and were seen at a GeoS

273 Of U.S. adult travelers who presented for pretravel consultation at GT

274 r malaria pose serious concern for long-term travelers who purchase their medications overseas.

275 Clinicians evaluating high-altitude travelers who report moderate to severe limitations in a

276 retravel healthcare from 13235 international travelers who sought pretravel consultation at these sit

277 OPG+1181G>C) was associated with TD in white travelers who stayed in Mexico for >1 week during the su

278 ts were (1) late initiation of rabies PEP in travelers who waited to seek medical care until returnin

279 Most MMR-eligible travelers who were not vaccinated were evaluated in the

280 An increasing number of travelers will have cardiovascular disease as the popula

281 Ill returned travelers with a confirmed, probable, or clinically susp

282 Patients: Ill returned travelers with a confirmed, probable, or clinically susp

283 nger in travelers returning from Asia and in travelers with a high relative abundance of MRE at retur

284 these examinations is limited, especially in travelers with a low worm burden.

285 es fragilis (ETBF), in 201 U.S. and European travelers with acute diarrhea acquired in Mexico, Guatem

286 in invasive fungal infections are likely co-travelers with advances in transplant practices.

287 Travelers with cardiovascular disease may be at increase

288 solates (as defined by HEp-2 adherence) from travelers with diarrhea and in 18 EAEC isolates from tra

289 (EAEC) infection can be identified in 26% of travelers with diarrhea and is associated with fecal int

290 Stool samples from 571 international travelers with diarrhea were evaluated for traditional e

291 Among the 28 ill returned travelers with human immunodeficiency virus (HIV) infect

292 phenomenon among EAEC isolates derived from travelers with or without diarrhea and that multiple gen

293 SNPs in the OPG gene for 968 North American travelers with or without TD.

294 Methods and Twenty-six returning travelers with schistosomiasis (based on positive result

295 uent in the lesional and nasal isolates from travelers with SSTIs but could not be found in the nares

296 Stool samples from travelers with TD were evaluated for the presence of ent

297 cal, and exposure-related characteristics of travelers with those of nontravelers and estimate the ri

298 Measles remains a risk for travelers, with 94 measles diagnoses reported to the Geo

299 s with diarrhea and in 18 EAEC isolates from travelers without diarrhea.

300 Common causes of chronic diarrhea among travelers worldwide include protozoan parasites.